Skip to main content

Advertisement

SpringerLink
Log in

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Adoptive cell therapy (ACT) of tumor infiltration lymphocytes (TIL) yields promising clinical results in metastatic melanoma patients, who failed standard treatments. Due to the fact that metastatic lung cancer has proven to be susceptible to immunotherapy and possesses a high mutation burden, which makes it responsive to T cell attack, we explored the feasibility of TIL ACT in non-small cell lung cancer (NSCLC) patients. Multiple TIL cultures were isolated from tumor specimens of five NSCLC patients undergoing thoracic surgery. We were able to successfully establish TIL cultures by various methods from all patients within an average of 14 days. Fifteen lung TIL cultures were further expanded to treatment levels under good manufacturing practice conditions and functionally and phenotypically characterized. Lung TIL expanded equally well as 103 melanoma TIL obtained from melanoma patients previously treated at our center, and had a similar phenotype regarding PD1, CD28, and 4-1BB expressions, but contained a higher percent of CD4 T cells. Lung carcinoma cell lines were established from three patients of which two possessed TIL cultures with specific in vitro anti-tumor reactivity. Here, we report the successful pre-clinical production of TIL for immunotherapy in the lung cancer setting, which may provide a new treatment modality for patients with metastatic NSCLC. The initiation of a clinical trial is planned for the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ACT:

Adoptive cell therapy

CM:

Complete medium

REP:

Rapid expansion procedure

TIL:

Tumor infiltrating lymphocytes

TRC:

Tissue remnant culture

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332

    Article  PubMed  Google Scholar 

  2. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1–12. https://doi.org/10.1016/j.lungcan.2009.12.009

    Article  PubMed  Google Scholar 

  3. Antonia SJ, Vansteenkiste JF, Moon E (2016) Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet 35:e450–e458. https://doi.org/10.14694/EDBK_158712

    Article  Google Scholar 

  4. Giri A, Walia SS, Gajra A (2016) Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer. Rev Recent Clin Trials 11:297–305

    Article  PubMed  CAS  Google Scholar 

  5. Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS (2016) Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 49:1324–1333. https://doi.org/10.1093/ejcts/ezv371

    Article  PubMed  Google Scholar 

  6. Shin DS, Ribas A (2015) The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol 33:23–35. https://doi.org/10.1016/j.coi.2015.01.006

    Article  PubMed  CAS  Google Scholar 

  7. Horne ZD, Jack R, Gray ZT et al (2011) Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 171:1–5. https://doi.org/10.1016/j.jss.2011.03.068

    Article  PubMed  CAS  Google Scholar 

  8. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ (2011) Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 167:207–210. https://doi.org/10.1016/j.jss.2009.08.029

    Article  PubMed  Google Scholar 

  9. Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218. https://doi.org/10.1038/nature12213

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Lu YC, Yao X, Crystal JS et al (2014) Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 20:3401–3410. https://doi.org/10.1158/1078-0432.CCR-14-0433

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Robbins PF, Lu YC, El-Gamil M et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752. https://doi.org/10.1038/nm.3161

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357. https://doi.org/10.1200/JCO.2005.00.240

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Itzhaki O, Hovav E, Ziporen Y et al. (2011) Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34:212–220. https://doi.org/10.1097/CJI.0b013e318209c94c

    Article  Google Scholar 

  14. Andersen R, Donia M, Ellebaek E et al (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 22:3734–3745. https://doi.org/10.1158/1078-0432.CCR-15-1879

    Article  PubMed  CAS  Google Scholar 

  15. Besser MJ, Shapira-Frommer R, Itzhaki O et al (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19:4792–4800. https://doi.org/10.1158/1078-0432.CCR-13-0380

    Article  PubMed  CAS  Google Scholar 

  16. Dudley ME, Gross CA, Somerville RP et al (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152–2159. https://doi.org/10.1200/JCO.2012.46.6441

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Goff SL, Dudley ME, Citrin DE et al (2016) Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol 34:2389–2397. https://doi.org/10.1200/JCO.2016.66.7220

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pilon-Thomas S, Kuhn L, Ellwanger S et al. (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615–620. https://doi.org/10.1097/CJI.0b013e31826e8f5f

    Article  CAS  Google Scholar 

  19. Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758–6770. https://doi.org/10.1158/1078-0432.CCR-12-1177

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Ratto GB, Zino P, Mirabelli S et al. (1996) A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78:244–251. https://doi.org/10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L

    Article  Google Scholar 

  21. Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35:283–292. https://doi.org/10.1097/CJI.0b013e31824e801f

    Article  Google Scholar 

  22. Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O et al (2017) Selection of shared and neoantigen reactive T cells for adoptive cell therapy based on CD137 separation. Front Immunol. https://doi.org/10.3389/fimmu.2017.01211

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hinrichs CS, Restifo NP (2013) Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 31:999–1008. https://doi.org/10.1038/nbt.2725

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

The authors would like to thank Haya and Nehemia Lemelbaum for their generous support.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Sheba Medical Center, 52621, Ramat Gan, Israel

    Ronny Ben-Avi & Alon Ben-Nun

  2. Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, 52621, Ramat Gan, Israel

    Ronit Farhi, Marina Gorodner, Eyal Greenberg, Gal Markel, Jacob Schachter, Orit Itzhaki & Michal J. Besser

  3. Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Gal Markel & Michal J. Besser

Authors
  1. Ronny Ben-Avi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronit Farhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alon Ben-Nun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marina Gorodner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eyal Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gal Markel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacob Schachter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Orit Itzhaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michal J. Besser
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RB-A, OI, and MJB designed the study. RB-A, OI, RF, AB-N, MG, and EG acquired the data. RB-A, OI, RF, GM, JS, and MJB analyzed and interpreted the data. All the authors revised the work, approved the final version, and agreed to be accountable of the work.

Corresponding authors

Correspondence to Orit Itzhaki or Michal J. Besser.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The protocol was approved by the IRB Committee of the Sheba Medical Center, Israel. Approval number: SMC-0921-13.

Informed consent

Patients signed an informed consent under the approved protocol SMC-0921-13.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 611 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ben-Avi, R., Farhi, R., Ben-Nun, A. et al. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 67, 1221–1230 (2018). https://doi.org/10.1007/s00262-018-2174-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-018-2174-4

Keywords

Search

Navigation